Literature DB >> 1590681

Efficacy of ciprofloxacin for treatment of Brucella melitensis infections.

M B al-Sibai1, M A Halim, M M el-Shaker, B A Khan, S M Qadri.   

Abstract

The effectiveness of treatment of human brucellosis caused by Brucella melitensis with ciprofloxacin alone was investigated in a prospective nonrandomized study. Subjects with central nervous system involvement, endocarditis, or severe renal dysfunction; children under 16 years of age; and pregnant women were excluded from the study. Of 19 patients, 16 completed the study; 7 were diagnosed as having acute systemic brucellosis, and 9 had acute brucella arthritis-diskitis. A rapid response to ciprofloxacin was seen in all 16 patients, but the blood cultures of 1 patient remained positive and the treatment was changed. During a 104-week follow-up period, 4 of the 15 responding patients relapsed or were reinfected within 8 to 32 weeks after completion of therapy. We conclude that treatment with ciprofloxacin alone, although effective for the acute symptoms, is associated with an appreciable rate of relapse; therefore, it should be given with other agents for treatment of brucellosis.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1590681      PMCID: PMC189243          DOI: 10.1128/AAC.36.1.150

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  12 in total

1.  Susceptibility of Brucella melitensis to fluoroquinolones.

Authors:  S M Qadri; M Akhtar; Y Ueno; M B al-Sibai
Journal:  Drugs Exp Clin Res       Date:  1989

Review 2.  Modern chemotherapy for brucellosis in humans.

Authors:  W H Hall
Journal:  Rev Infect Dis       Date:  1990 Nov-Dec

3.  Ciprofloxacin: an overview and prospective appraisal.

Authors:  H C Neu
Journal:  Am J Med       Date:  1987-04-27       Impact factor: 4.965

4.  Treatment of Salmonella typhi carrier state with ciprofloxacin.

Authors:  S J Hudson; H R Ingham; M H Snow
Journal:  Lancet       Date:  1985-05-04       Impact factor: 79.321

5.  In vitro activity of ciprofloxacin against Brucella melitensis.

Authors:  M Gobernado; E Cantón; M Santos
Journal:  Eur J Clin Microbiol       Date:  1984-08       Impact factor: 3.267

6.  In vitro susceptibility of Brucella to various antibiotics.

Authors:  W H Hall; R E Manion
Journal:  Appl Microbiol       Date:  1970-10

7.  Failure of prolonged treatment with ciprofloxacin in acute infections due to Brucella melitensis.

Authors:  R Lang; R Raz; T Sacks; M Shapiro
Journal:  J Antimicrob Chemother       Date:  1990-12       Impact factor: 5.790

8.  Analysis of 506 consecutive positive serologic tests for brucellosis in Saudi Arabia.

Authors:  F W Kiel; M Y Khan
Journal:  J Clin Microbiol       Date:  1987-08       Impact factor: 5.948

9.  Effect of ciprofloxacin on intracellular organisms: in-vitro and in-vivo studies.

Authors:  C S Easmon; J P Crane; A Blowers
Journal:  J Antimicrob Chemother       Date:  1986-11       Impact factor: 5.790

10.  In-vitro activity of ciprofloxacin, ceftriaxone and five other antimicrobial agents against 95 strains of Brucella melitensis.

Authors:  J Bosch; J Liñares; M J López de Goicoechea; J Ariza; M C Cisnal; R Martin
Journal:  J Antimicrob Chemother       Date:  1986-04       Impact factor: 5.790

View more
  17 in total

Review 1.  Update on detection of bacteremia and fungemia.

Authors:  L G Reimer; M L Wilson; M P Weinstein
Journal:  Clin Microbiol Rev       Date:  1997-07       Impact factor: 26.132

2.  In vitro activities of antibiotics alone and in combination against Brucella melitensis at neutral and acidic pHs.

Authors:  M Akova; D Gür; D M Livermore; T Kocagöz; H E Akalin
Journal:  Antimicrob Agents Chemother       Date:  1999-05       Impact factor: 5.191

3.  Functional characterization of Brucella melitensis NorMI, an efflux pump belonging to the multidrug and toxic compound extrusion family.

Authors:  Martine Braibant; Laurence Guilloteau; Michel S Zygmunt
Journal:  Antimicrob Agents Chemother       Date:  2002-09       Impact factor: 5.191

4.  Neurobrucellosis in children, a report of 2 cases.

Authors:  Mohammed S Al Ayed
Journal:  Int J Health Sci (Qassim)       Date:  2011-01

Review 5.  Quinolones for treatment of human brucellosis: critical review of the evidence from microbiological and clinical studies.

Authors:  Matthew E Falagas; Ioannis A Bliziotis
Journal:  Antimicrob Agents Chemother       Date:  2006-01       Impact factor: 5.191

6.  In vitro activities of six new fluoroquinolones against Brucella melitensis.

Authors:  I Trujillano-Martín; E García-Sánchez; I M Martínez; M J Fresnadillo; J E García-Sánchez; J A García-Rodríguez
Journal:  Antimicrob Agents Chemother       Date:  1999-01       Impact factor: 5.191

7.  Spontaneous peritonitis due to Brucella melitensis in a patient with cirrhosis.

Authors:  F Demirkan; H E Akalin; H Simşek; E Ozyilkan; H Telatar
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1993-01       Impact factor: 3.267

Review 8.  Quinolones in intracellular infections.

Authors:  J C Pechère
Journal:  Drugs       Date:  1993       Impact factor: 9.546

9.  Quinolones in treatment of human brucellosis: comparative trial of ofloxacin-rifampin versus doxycycline-rifampin.

Authors:  M Akova; O Uzun; H E Akalin; M Hayran; S Unal; D Gür
Journal:  Antimicrob Agents Chemother       Date:  1993-09       Impact factor: 5.191

10.  Therapy of experimental murine brucellosis with streptomycin alone and in combination with ciprofloxacin, doxycycline, and rifampin.

Authors:  R Lang; B Shasha; E Rubinstein
Journal:  Antimicrob Agents Chemother       Date:  1993-11       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.